欧索拉利祖马布与甲托雷克萨特或不含甲托雷克萨特在类风湿性关节炎患者中的作用:后期分析
Yoshiya Tanaka1, Nobuko Horiuchi2, Cosmo Sasajima2
1The First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, 1-1 Iseigaoka, Kitakyushu, Fukuoka, 807-8555, Japan. tanaka@med.uoeh-u.ac.jp.
Rheumatology and therapy
|January 27, 2025
概括
与安慰剂相比,OZR单一治疗改善了类风湿性关节炎 (RA) 症状. 结合OZR与甲状腺素 (MTX) 治疗中度至重度的RA,其疗效高于单独使用OZR.
科学领域:
- 类风湿病学 类风湿病学
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 奥佐拉利祖马布 (OZR) 是一种针对瘤亡因子 (TNF) 的新型生物疗法.
- 在日本,OZR已被批准用于类风湿性关节炎 (RA) 患者,这些患者对现有治疗反应不足.
- 这项研究评估了使用和不使用甲状腺素 (MTX) 的OZR疗效.
研究的目的:
- 为了比较Ozoralizumab (OZR) 单一治疗与安慰剂 (MTX延续) 的疗效.
- 为了比较OZR与甲醇 (MTX) 结合治疗的疗效与OZR单一治疗.
- 评估类风湿性关节炎患者的治疗结果.
主要方法:
- 对NATSUZORA (OZR单疗法) 和OHZORA (OZR + MTX) 试验数据进行后期分析.
- 倾向性得分匹配用于调整治疗组之间的共变量.
- 美国风湿病学会 (ACR) 20/50/70反应率和重复措施的混合效应模型进行了分析.
主要成果:
- 与安慰剂 (MTX延续) 相比,OZR单疗显示出明显更高的ACR20,ACR50和ACR70反应率.
- 在OZR和OZR+MTX组之间,ACR20反应没有显著差异.
- 与OZR单独治疗相比,OZR + MTX联合治疗显示出明显更高的ACR50和ACR70反应率.
结论:
- 与安慰剂相比,单独治疗ozolizumab在RA症状上提供了显著的临床改善.
- 对于类风湿性关节炎,使用奥索拉利祖马布和甲铁酸的联合治疗比单独使用奥索拉利祖马布更有效.
- 这些发现支持OZR作为RA的有价值的治疗选择,与MTX相结合时可以获得更大的好处.
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
141
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
141
Drugs for Treatment of Ulcerative Colitis in IBD
118
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
118
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
114
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
114
Antiasthma Drugs: Leukotriene Modifiers
239
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
239
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
234
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
234


